-
Thioguanine Workflows for Cancer and EV71 Studies
2026-09-09
Build reproducible 6-thioguanine experiments across cancer-cell, antiviral, and epigenetic models with practical guidance on dosing, controls, and orthogonal readouts. The workflow also adapts lessons from a classic genetic-toxicology study without confusing its glutaraldehyde findings with direct Thioguanine evidence.
-
A-769662: Reading AMPK Under Energy Stress
2026-09-09
A-769662 is a reversible AMPK activator for dissecting metabolic signaling without equating pharmacological activation with cellular energy starvation. This article translates new AMPK–ULK1 findings into practical assay design, controls, and interpretation for metabolism and proteasome studies.
-
Marein Reverses ABCG2-Mediated Chemoresistance
2026-09-08
The reference study identifies marein, a chalcone-type flavonoid from Coreopsis tinctoria Nutt, as a competitive inhibitor of the ABCG2 drug transporter. By increasing intracellular exposure to ABCG2 substrates, marein restored cancer-cell sensitivity to mitoxantrone, topotecan, and olaparib, supporting transporter-focused strategies for studying multidrug resistance.
-
Omeprazole A2845: Research Workflow Guide
2026-09-08
Omeprazole A2845 provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, antiulcer activity study workflows, and related assay development. Its limited water and ethanol solubility requires DMSO-based preparation and vehicle controls; it is intended only for scientific research and not for diagnostic, therapeutic, or medical use.
-
HSP90 and RNA Foci Regulation in DM1
2026-09-07
Johnson and colleagues used an unbiased small-molecule screen to identify HSP90 as a regulator of pathogenic DMPK RNA and CUG-repeat RNA foci in myotonic dystrophy type 1. The study further connects HSP90 activity to p-STAT3 in undifferentiated myoblasts while showing that HSP90 effects reverse after differentiation, emphasizing cell state as a critical variable in DM1 mechanism studies.
-
CB-839 (Telaglenastat) in Cancer Metabolism
2026-09-05
CB-839 (Telaglenastat) gives researchers a direct, reversible way to test whether glutaminase 1 dependence drives tumor-cell fitness, apoptosis, or autophagy. This workflow connects glutaminolysis inhibition assays with the spliceosomal and epitranscriptomic vulnerabilities reported in MYCN-amplified neuroblastoma.
-
Endogenous H2S Deficiency in Diabetic Cardiomyopathy
2026-09-05
The reference study identifies reduced endogenous hydrogen sulfide production as a mechanistic contributor to lipid-induced myocardial injury in diabetic cardiomyopathy. Using patient samples, diabetic rats, and palmitate-treated cardiomyocytes, it links H2S deficiency with endoplasmic reticulum stress and shows that H2S donation or ER-stress inhibition reduces cardiac lipotoxicity.
-
Zolmitriptan Workflows for 5-HT1B Research
2026-09-04
Build reproducible receptor-signaling, vascular, and neuropeptide assays with Zolmitriptan, a selective serotonin ligand for migraine and cluster headache research. This guide combines solvent handling, subtype-resolved experimental design, orthogonal controls, and lysosome-inspired workflow logic without overstating evidence across disease domains.
-
Macrophage–Adipoq+ Signaling in S. aureus Osteomyelitis
2026-09-04
A 2025 Nature Communications study identifies a host stromal mechanism that helps Staphylococcus aureus abscesses persist in bone marrow: macrophage-derived amphiregulin drives Adipoq+ marrow precursors toward a perfusion-limiting myofibroblast state. Genetic and pharmacological disruption of the AREG–EGFR–mTOR–YAP axis reduced fibrosis, improved antibiotic delivery, and enhanced bacterial clearance in a mouse osteomyelitis model.
-
miR-196a Drives EAC Through the MYC/TERT/NFκB Axis
2026-09-03
The reference study moves beyond biomarker association by showing that miR-196a can actively promote an aggressive esophageal adenocarcinoma phenotype through coordinated MYC, TERT, and NFκB signaling. Its combination of cell-based perturbation, mechanistic rescue experiments, and Barrett’s esophagus tissue analysis identifies a testable pathway linking disease progression with epithelial-to-mesenchymal transition and cell motility.
-
HyperScript RT SuperMix for qPCR in NSCLC
2026-09-03
Apply a high-temperature, mixed-primer reverse transcription workflow to quantify SPI1 and related transcripts in NSCLC models, including low-input RNA samples. The protocol also clarifies when mature miRNA targets such as miR-616-5p require a dedicated small-RNA assay rather than conventional cDNA synthesis alone.
-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-09-02
Zhao and colleagues present a standardized whole-blood stimulation protocol that combines innate immune challenges with targeted metabolic perturbations and cytokine measurement. The workflow preserves the multicellular context of blood while improving comparability across donors and cohorts, making it useful for studying how anabolic and catabolic pathways shape immune function.
-
2-NBDG Glucose Uptake Assay Kit for HCC Metabolism
2026-09-02
The 2-NBDG Glucose Uptake Assay Kit provides a rapid, non-radioactive way to connect transporter activity with therapy-response phenotypes in hepatocellular carcinoma models. Its 96-well format, single-cell compatibility, and phloretin specificity control make it useful for screening sorafenib-resistant cells, organoids, and metabolic interventions.
-
BIBR 1532 Telomerase Inhibitor Workflows
2026-09-01
BIBR 1532 enables mechanism-focused studies that connect hTERT inhibition with cancer cell proliferation, transcriptional responses, and apoptosis. This practical guide shows how to build robust telomerase activity assay workflows, compare telomere-targeting strategies, and troubleshoot short-term versus long-term readouts.
-
Light-Inducible RNA Switches for Gene Therapy
2026-08-31
The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the translational level. In mouse models, LIRP enabled light-responsive treatment of diet-induced obesity and retinal neovascular disease, illustrating how reversible optogenetic control could improve the timing and safety of gene therapy.